

- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)



### Drugs of Abuse

- [Companies](#)
- [Professional Products](#)
- [Disease Areas](#)
- [Cardiology](#)
- [Drugs of Abuse](#)
- [Infectious Disease](#)
- [Oncology](#)
- [Women's Health](#)
- [Brands](#)
- [Health Management](#)
- [Consumer](#)

### [Professional Products](#) [Disease Areas](#)

Despite advances in medical, social, and economic sciences, substance abuse continues to be a significant problem in the United States and other countries worldwide. The ability to obtain a differential diagnosis of drug use in a timely manner greatly aids the course of medical treatment, including the prevention of contraindicated medicinal interventions. In addition to the diagnostic applications, drugs of abuse screening programs are extensively utilized in occupational and law enforcement settings.

Inverness Medical Innovations offers the broadest available portfolio of point of care drugs of abuse products. Our current product platforms encompass the following technologies:

- meter-based fluorescence immunoassay
- patented ASCEND MultiImmunoAssay®
- visually-interpreted lateral flow immunoassay

With a broad testing menu and variety of product formats, Inverness Medical Innovations is able to provide point of care testing option for virtually any setting.

Products available:

[Triage® TOX Drug Screen](#)

[Triage® Drugs of Abuse Panels](#)  
[iScreen™ One Step Drug Tests](#)

[SureStep™ DST](#)